

REMARKS

Claims 95, 96 and 102-104 and 111 were pending. Claim 96 has been canceled without prejudice. Claims 95, 102-104, and 111 have been amended. New claims 112-115 have been added.

Claim 95 has been amended to specify that the composition includes a mixture of an isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO:6 and an isolated polypeptide consisting of residues 14-39 of SEQ ID NO:6, or an epitope-containing portion thereof. Support for this amendment can be found throughout the application as originally filed, for example, at page 32, line 34, through page 33, line 1.

Claims 102-104 have been amended to provide appropriate antecedent basis.

Claim 111 has been amended to specify an isolated polypeptide consisting of Fel 31-2 (residues 14-39 of SEQ ID NO:6) and a pharmaceutical acceptable carrier. Support for this amendment can be found throughout the application as originally filed, for example, at page 3, lines 2-5, and page 19, lines 14-33.

Claims 112-115 are drawn to compositions comprising the peptide of claim 111 combined with a second isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO:6, and/or a fragment of a protein allergen comprising the amino acid sequence set forth in SEQ ID NO:6, for example, a fragment capable of stimulating T cells. Support for new claims 112-115 can be found throughout the application as originally filed, for example, at page 3, lines 2-5, and at page 32, line 34, through page 33, line 1.

The foregoing claim amendments should in no way be construed as acquiescence to any of the Examiner's rejections and were made solely to expedite prosecution of the application. Applicants reserve the right to pursue claims to the canceled subject matter, or any subject matter which they are entitled to claim, in this or a separate application. No new matter has been added.

Obviousness-Type Double Patenting Rejection

Claims 95, 96, 102-104 and 111 have been rejected as allegedly being unpatentable over claims 1-33 of U.S. Patent No. 6,019,972 and over claims 1-24 of U.S. Patent No. 5,547,669. Applicants respectfully submit, while in no way admitting that the present claims are obvious over claims 1-33 of U.S. Patent No. 6,019,972 and over claims 1-24 of U.S. Patent No. 5,547,669, that, upon allowance of the present claims, Applicants will submit a terminal disclaimer in compliance with 37 C.F.R. 1.321(b) and (c), if appropriate, which will obviate the rejection.

Rejection of Claims 102-104 Under 35 U.S.C. §112, Second Paragraph

Claims 102-104 are rejected as being indefinite. Claims 102-104 have been amended to provide appropriate antecedent basis. Therefore, this rejection is moot.

Rejection of Claims 95, 96, and 102-104 Under 35 U.S.C. §102(b)

Claims 95, 96, and 102-104 are rejected under 35 U.S.C. § 102(b) as allegedly being anticipated by Leiterman *et al.* *J. Allergy Clin. Immunol.*, 74:147-153 (1984). Applicants respectfully traverse this rejection and refer to their arguments of record. However, to expedite prosecution, the claims have been amended to specify an isolated polypeptide consisting of amino acid residues 14-39 of SEQ ID NO:6. Leiterman *et al.* fail to teach or suggest the claimed peptide, as well as compositions comprising such a peptide. Accordingly, the claims are novel over the cited reference.


CONCLUSION

If a telephone conference with Applicants' Attorney would expedite prosecution of the application and allowance of the claims, the Examiner is urged to contact the undersigned representative at (617) 227-7400.

Applicants herewith submit the requisite fee associated with the filing of this Amendment. However, should any additional fee be due, please charge such fee to our Deposit Account No. 12-0080, under Order No. IMI-044DV3CNRCE3, from which the undersigned is authorized to draw.

Dated: October 25, 2007

Respectfully submitted,

By 
Jeanne M. DiGiorgio
Registration No.: 41,710
LAHIVE & COCKFIELD, LLP
One Post Office Square
Boston, Massachusetts 02109
(617) 227-7400
(617) 742-4214 (Fax)
Attorney/Agent For Applicants